ISSN: 0924-977X

Journal Home

Journal Guideline

European Neuropsychopharmacology Q1 Unclaimed

Elsevier B.V. Netherlands

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

European Neuropsychopharmacology is a journal indexed in SJR in Pharmacology and Neurology (clinical) with an H index of 130. It has an SJR impact factor of 1,756 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,756.

European Neuropsychopharmacology focuses its scope in these topics and keywords: dopamine, functioning, early, system, neuronal, response, monoamine, receptor, clinical, calendar, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Biological Psychiatry (Q1) Neurology (Q1) Neurology (clinical) (Q1) Neurology (clinical) (Q1) Pharmacology (Q1) Pharmacology (medical) (Q1) Pharmacology (medical) (Q1) Psychiatry and Mental Health (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,756

SJR Impact factor

130

H Index

134

Total Docs (Last Year)

450

Total Docs (3 years)

6187

Total Refs

2034

Total Cites (3 years)

346

Citable Docs (3 years)

4.22

Cites/Doc (2 years)

46.17

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Pharmacological Reviews Q1
Drug Resistance Updates Q1
Annual Review of Pharmacology and Toxicology Q1
Molecular Therapy Q1
Journal for ImmunoTherapy of Cancer Q1

Compare this journals

Aims and Scope

Best articles by citations

Tryptophan depletion and neurohormonal regulation in remitted patients with seasonal affective disorder

P.1.005 Trazodone and priapism

P.1.010 MAO-A and MAO-B differ in their stereoselective biotransformation of citalopram in human liver

P.1.026 An open study with sertraline in outpatients with dysthymia

P.1.036 Efficacy of the association selective serotonin reuptake inhibitors + benzamides in the treatment of dysthymia

P.1.041 Effect of pindolol in hastening response to serotoninergic antidepressants: An open study in severely depressed female in-patients

P.1.048 Effects of first-trimester fluoxetine exposure on the newborn

P.1.054 Combined antidepressant therapy using mirtazapine and citalopram in therapy resistent depression

P.1.062 Patient-rated improvements for sertraline non-responders treated with fluoxetine

P.1.063 A comparative study of sertraline vs. imipramine in post-psychotic depressive disorder of schizophrenia

P.1.079 The pharmacological profile of venlafaxine, a new antidepressant drug given acutely and chronically

Effect of nicotine on sniffing induced by dopaminergic receptor stimulation

SHOW MORE ARTICLES

P.1.093 Trends in treating bipolar disorder during the last six years at a university clinic in Turkey

P.1.098 Early phase II results of the RIMA RS-8359

P.1.105 Does a lower initial starting dosage improve tolerability for once-daily venlafaxine XR?

P.1.111 Relationships between selected immunological parameters and cortisol in treatment resistant depression

P.1.119 Adjunctive long term treatment of therapy resistant circular psychoses with flupentixoldecanoat

Prevalence and characteristics of patients with pseudoakathisia

P.1.149 Neuroendocrine responses to the citalopram challenge test in major depression

P.1.155 Steroid-independent translocation of the glucocorticoid receptor by the antidepressant, desipramine

P.1.161 Treatment of atypical depression with sertraline: A double-blind comparative trial with moclobemide

L-5 Critical progress in MAO inhibition in the treatment of mood disorders

P.1.167 Citalopram in the treatment of depression in patients suffering from simultaneous serious somatic disorders

P.1.172 Social aspects of mild antidepressants therapy of youth depressions accompanied by drug use